Suzanne Merrill

2 weeks ago | urologytimes.com | Suzanne Merrill |Benjamin P. Saylor

ImmunityBio has been awarded patents for the combination of BCG plus nogapendekin alfa inbakicept (Anktiva) in bladder cancer. In a recent interview with Urology Times®, Suzanne B. Merrill, MD, FACS, was asked how she foresees the integration of this combination therapy, alongside the availability of recombinant BCG, influencing future treatment paradigms for non–muscle invasive bladder cancer.

3 weeks ago | urologytimes.com | Suzanne Merrill |Benjamin P. Saylor

For years, urologists and patients have dealt with the effects of the BCG shortage. A new expanded access program (EAP) authorized by the FDA, in which ImmunityBio is partnering with the Serum Institute of India to provide recombinant BCG (rBCG), seeks to alleviate the effects of the current shortage.1In an interview with Urology Times®, Suzanne B. Merrill, MD, FACS, discussed the impact of the BCG shortage.

4 weeks ago | urologytimes.com | Suzanne Merrill |Benjamin P. Saylor |Hannah Clarke

An expanded access program (EAP) to provide recombinant BCG (rBCG) in the US was recently authorized by the FDA.1For the EAP, ImmunityBio has partnered with the Serum Institute of India, which develops rBCG, to provide an alternative source across the US. In an interview with Urology Times®, Suzanne B. Merrill, MD, FACS, provided an overview of the EAP. “One important aspect to get across…is that access to this EAP is pretty easy. What one would do is go to the ImmunityBio website.